Legal challenges of US Food and Drug Administration exclusivity determinations are among the early cases where the Supreme Court’s overturning of the Chevron doctrine of deference is being cited.
The 28 June decision in Loper Bright v. Raimondo and Relentless v. Department of Commerce is being used in drug and biologic litigation by plaintiffs, who assert FDA decision-making should...
Key Takeaways
-
Parties involved in litigation with the FDA over drugs and biologics are starting to cite the Supreme Court’s Loper Bright decision in court filings.
- ...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?